Virtual rehabilitation program for cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of an 8-week virtual cancer rehabilitation program called CaRE@Home for survivors of various cancers, including breast, colorectal, head and neck cancers, and lymphoma. The program aims to improve overall disability and enhance physical and social functioning, anxiety, work status, quality of life, and physiological changes. Participants will engage in weekly online group exercise classes and self-management education, with follow-up assessments at 3 and 6 months to monitor progress. The study is conducted across multiple centers in Canada to assess both clinical effectiveness and implementation potential.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) Age 18 years or older
* 2\) Diagnosed with breast (stage 0-III), colorectal (stage I-III), head and neck (stage I-III), or lymphoma/lymphoproliferative disorder (excluded: recurrent, refractory, progressive, received or planning to receive transplant)
* 3\) Completed a primary treatment (i.e. surgery and/or radiation and/or systemic therapy of any kind) within the last 24 months
* 4\) If patients received systemic therapy of a fixed duration with adjuvant/curative intent, the main part should be completed, but patients are eligible if on primary, maintenance, or other adjuvant systemic therapy (e.g. eligible while on trastuzumab, immunotherapy, rituximab, oral endocrine or targeted therapy - ie ibrutinib). Indolent non-curative lymphoma patients are eligible if they have response to systemic therapy
* 5\) Communicate sufficiently in English to complete intervention and questionnaires
* 6\) Willing to be randomized and participate in the intervention and attend in-person or virtual assessments
* 7\) Internet access
* 8\) An indication for cancer rehabilitation (WHO-DAS score \>5).

Exclusion Criteria:

* 1\) Impaired functional status that would preclude rehabilitation (PRFS \>3)
* 2\) Indication of major depressive disorder (\> or = to 20 on PHQ-9)
* 3\) Diagnosis of neurological disease or condition significantly limiting cognitive functioning, such as language or memory (e.g., Alzheimer's disease or other dementia, severe traumatic brain injury);
* 4\) Currently enrolled in another personalized and supervised exercise or rehabilitation program
* 5\) Conditions or current injuries which are not appropriate for distance based exercise (based on intake screening questions and as determined by physician\*. \*In cases where patient's indicate an existing higher risk condition (i.e high blood pressure, recent heart attach or unstable angina, spinal cord compression, recent deep vein thrombosis) or injury, the study team will contact the physician for medical approval and clearance to participate in the study will be required)

Where it's running

• Princess Margaret Cancer Centre
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Jennifer Jones, PhD — UHN Princess Margaret Cancer Centre
• Study coordinator: charmaine silva, MSc
• Email: charmaine.silva@uhn.ca
• Phone: 4165818543

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Improving surgical decisions for young women with breast cancer

  This study is testing a new online tool to help young women with breast cancer make better surgical decisions and communicate more effectively with their doctors.

  Recruiting at 4 sites Weill Medical College of Cornell University · New Haven, Connecticut and 3 other locations · NCT06275126

• Capecitabine for MRD-positive, resected ER+/HER2-negative breast cancer

  This Phase 2 trial tests whether taking capecitabine can help people with resected, ER-positive/HER2-negative breast cancer who still have molecular residual disease after standard therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT07631052

• Predicting how hormone therapy before surgery affects breast cancer

  This study is testing how hormone therapy before surgery can help people with early-stage breast cancer and what it means for their tumors.

  Recruiting Phase 2 George Washington University · Washington D.C., District of Columbia · NCT06806930

• Meal timing during cancer treatment for Alaska Native and American Indian patients

  This test will see if an 8-hour time-restricted eating schedule during neoadjuvant or adjuvant therapy helps Alaska Native and American Indian adults with rectal or certain breast cancers.

  Recruiting Fred Hutchinson Cancer Center · Anchorage, Alaska · NCT06802172

• Memantine plus structured exercise to protect thinking and memory during breast cancer chemotherapy

  This will test whether memantine combined with a supervised exercise program, memantine alone, or a placebo can prevent or reduce thinking and memory problems in people receiving chemotherapy for stage I–III breast cancer.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06727773

• Blood test for early detection of colorectal cancer and adenomas

  This study is testing a new blood test to see if it can help find early signs of colorectal cancer and adenomas in people who are already scheduled for a colonoscopy.

  Recruiting at 6 sites City of Hope Medical Center · Monrovia, California and 5 other locations · NCT06342440

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.